EC
BMRN icon

Elmind Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elmind Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.69M Hold
47,000
– – 0.68% 26
2026
Q1 		$2.66M Sell
47,000
-35,000
-43% -$2.04M 0.75% 25
2025
Q4 		$4.87M Buy
+82,000
New +$4.46M 1.44% 19

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Elmind Capital's BMRN Position: Q2 2026 in Review

Elmind Capital held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 47,000 shares worth $2.69M. The position accounts for 0.68% of the portfolio, ranked #26.

Elmind Capital first reported a position in BMRN in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.87M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Elmind Capital held 47,000 shares of BioMarin Pharmaceuticals worth $2.69M as of Q2 2026.
  • Elmind Capital left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.68% of Elmind Capital's portfolio in Q2 2026, its #26 holding.
  • Elmind Capital first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Elmind Capital's BioMarin Pharmaceuticals position peaked at $4.87M in Q4 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.